Richard Leduc

Prix et distinctions

• Co-recipient, Prix de la Recherche et de la Création, Université de Sherbrooke. Université de Sherbrooke. (Distinction).
• Co-recipient, Regroupements sectoriels de recherche industrielle (RSRI). Association pour le développement de la recherche et de l’innovation du Québec (ADRIQ). (Distinction).
• First recipient in Canada of GSK's Discovery Partnership with Academia. GSK. (Prize / Award).
• Mérite 'Estrien'. La Tribune. (Prize / Award).
• Mérite 'Estrien'. La Tribune newspaper.

Financement

• Grant. (Awarded). Principal Applicant. Targeting TMPRSS6 for treating hepcidin-deficiency disorders. Canadian Institutes of Health Research (CIHR). Project. 960 000 $. (2021-2026)
• Grant. (Awarded). Principal Applicant. Structural and functional understanding of angiotensin II type 1 receptor biased signaling (25% to be awarded to the Leduc lab). Canadian Institutes of Health Research (CIHR). Project grant. 1 190 000 $. (2020-2025)
• Grant. (Awarded). Co-applicant. Impact of novel ubiquitin-based Galphas regulation on receptor signalling and trafficking (25% to be awarded to R. Leduc). Canadian Institutes of Health Research (CIHR). Project grant. 665 550 $. (2019-2024)
• Grant. (Awarded). Co-applicant. Tumor-promoting functions of TMPRSS13 in breast cancer progression (5% to be awarded to R. Leduc). National Institutes of Health (NIH) (USA). RO1. 4 000 000 $. (2018-2023)
• Grant. (Awarded). Co-applicant. Targeting cancer stem cells to fight leukemia relapses (10% to be awarded to R. Leduc). Oncopole Quebec. Project program. 3 000 000 $. (2018-2023)
• Grant. (Awarded). Collaborator. Collaboration IRIC/ Universite/industrie: découverte accélérée de thérapies de l'économie pour un impact durable-FACS (2% to be awarded to R. Leduc). Government of Quebec. FACS. 10 000 000 $. (2019-2022)
• Grant. (Awarded). Principal Applicant. Preventing SARS-CoV-2 infection by targeting human type II transmembrane serine protease activity (50% to be awarded to the Leduc Lab). Canadian Institutes of Health Research (CIHR). Coronavirus initiative. 840 000 $. (2020-2022)
• Grant. (Completed). Principal Applicant. Characterization of GPR3 as a novel pharmacological target for Alzheimer's disease. Alzheimer Society of Canada. Grant. 150 000 $. (2016-2018)
• Contract. (Completed). Principal Applicant. Development of TMPRSS6 inhibitors for iron overload diseases. GlaxoSmithKline. DPAC. 1 500 000 $. (2015-2018)

Publications

Articles de revue

• Tirosh Shapira , Isaac Monreal , Sébastien Dion , David Buchholz , Brian Imbiakha , Andrea Olmstead , Mason Jager , Antoine Désilets , Guang Gao , Mathias Martins , Thierry Vandal , Connor Thompson , Aaleigha Chin , William Rees , Theodore Steiner , Ivan Nabi , Julie Sahler , Diego Diel , Gerlinde Van de Walle , Avery August , Gary Whittaker , Pierre-Luc Boudreault , Richard Leduc , Hector Aguilar and François Jean. (2022). A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature 605 340-348. DOI. (Published).
• Moreno-Salinas, A.L., Holleran, B., Ojeda-Muñiz, E.Y., Correoso-Braña, K., Ribalta-Mena, S., Ovando-Zambrano, J.C., Leduc, R., and Boucard, A. (2022). Convergent selective signaling impairment exposes the pathogenicity of latrophilin-3 missense variants linked to inheritable ADHD susceptibility. Molecular Psychiatry 27 2425-2438. DOI. (Published).
• Dion, S.P., Désilets, A., Lemieux, G., and Leduc, R. (2022). Functionally impaired isoforms regulate TMPRSS6 proteolytic activity. PLoS One 17 DOI. (Published).
• Pétigny, C., Dumont, A-A., Giguère, H., Collette, A., Holleran, B.J., Iftinca, M., Altier, C., Besserer-Offroy, E., Auger-Messier, M., Leduc, R. (2022). Monitoring TRPC7 conformational changes by BRET following GPCR activation. Int J Mol Sci 23 2502. DOI. (Published).
• Tirosh Shapira, I Abrrey Monreal, Sébastien P Dion, Mason Jager, Antoine Désilets, Andrea D Olmstead, Thierry Vandal, David W Buchholz, Brian Imbiakha, Guang Gao, Aaleigha Chin, William D Rees, Theodore Steiner, Ivan Robert Nabi, Eric Marsault, Julie Sahler, Avery August, Gerlinde Van de Walle, Gary R Whittaker, Pierre-Luc Boudreault, Hector C Aguilar, Richard Leduc, François Jean. (2021). A novel highly potent inhibitor of TMPRSS2-like proteases blocks SARS-CoV-2 variants of concern and is broadly protective against infection and mortality in mice. bioRxiv May 4 x. DOI.
• Poret, B., Desrues, L, Bonin, M.A., Pedard, M., Dubois, M., Leduc, R., Modzelewski, R., Decazes, P., Morin, F., Vera, P., Castel, H., Bohn, P., Gandolfo, P. (2020). Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours. Biomolecules 10 417-482. DOI. (Published).
• Murza, A., Dion, S.P., Boudreault, P-L., Désilets, A., Leduc, R and Marsault, E. (2020). Inhibitors of Type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of the patent literature. Expert Opinion On Therapeutic Patents 30 807-824. DOI. (Published).
• Lanchec, E.*, Désilets, A.*, Béliveau, F.* Leduc, R.# and Lavoie, C.# #co-corresponding authors. (2020). Matriptase processing of APLP1 ectodomain alters its homodimerization. Sci Rep 10 10091. DOI. (Published).
• (supervised *) Béliveau, F.*, Tarkar, A.,Dion, S.P.*, Désilets, A.*, Ghinet, M.G.*, Boudreault, P.L., St-Georges, C.*, Marsault, É., Paone, D., Collins, J., Macphee, C.H., Campobasso, N., Groy, A., Cottom, J., Ouellette, M., Pope, A.J., and Leduc, R. (2019). Discovery and development of TMPRSS6 inhibitors modulating hepcidin levels in human hepatocytes. Cell Chemical Biology 26 1559-1572. DOI. (Published).
• Connolly, A.*, Holleran, B.*, Simard, É.*, Baillargeon, J.P., Lavigne, P., and Leduc R. (2019). Interplay between intracellular loop 1 and helix VIII of the angiotensin II type 2 receptor controls its activation. Biochem Pharmacol 168 330-338. DOI. (Published).
• St-Pierre, D.*, Cabana, J.*, Holleran, B.J.*, Besserer-Offroy, E.*, Escher, E., Guillemette, G., Lavigne, P., and Leduc R. (2018). Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms. Biochem Pharmacol 154 104-117 *supervised. DOI. (Published).
• Ndong, D.B., Blais, V., Holleran, B.J., Proteau-Gagné, A., Cantin-Savoie, I., Robert, W., Nadon, J.F., Beauchemin, S., Leduc, R., Pineyro, G., Guérin, B., Gendron, L., and Dory, Y.L. (2018). Exploration of the fifth position ofLeu-enkephalin and its role in binding and activating delta (DOP) and mu (MOP)opioid receptors. Peptide Sci x y. (Published).
• Dion, S.*, Béliveau, F.*, Morency, L.P., Désilets, A.*, Najmanovich, R., Leduc, R. (2018). Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines. Sci Rep 8 12562 *supervised. DOI. (Published).
• Namkung Y., LeGouill C., Kumar S., Cao Y., Teixeira L.B., Lukasheva V., Giubilaro J., Simões S.C., Longpré J.M.*, Devost D., Hébert T.E., Piñeyro G., Leduc R., Costa-Neto C.M., Bouvier M., Laporte S.A. (2018). Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. Sci Signal 11 1-20. DOI. (Published).
• Tutunea-Fatan, E., Abd-Elrahman, K.S., Thibodeau, J.F., Holterman, C.E., Holleran, B.J.*, Leduc, R., Kennedy, C.R.J., Gros, R., Ferguson, S.S.G. (2018). GRK2 knockdown in mice exacerbates kidney injury and alters renal mechanisms of blood pressure regulation. Sci Rep 8 11415. DOI. (Published).
• Sousbie, M.*, Besserer-Offroy, E.*, Brouillette, R.L., Longpré, J.M., Leduc, R., Sarret, P., Marsault, É. (2018). In search of the optimal macrocyclization site for neurotensin. ACS Med Chem Lett 9 227-232. DOI. (Published).
• Lavenus, S.*, Simard, E.*, Besserer-Offroy, E.*, Froehlich, U., Leduc, R.#, and Grandbois, M#. # Co-corresponding authors. (2018). Label-free cell signaling pathway deconvolution of Angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct AngII and AngIII/IV responses. Pharmacol Res 18 30320-30327. DOI. (Published).
• Sousbie, M.*, Vivancos, M., Brouillette, R.L., Besserer-Offroy, E.*, Longpre, J.M., Leduc, R., Sarret, P., Marsault, E. (2018). Structural optimization and characterization of potent analgesic macrocyclic analogues of neurotensin 8-13. J Med Chem 16 7103-7115. DOI. (Published).
• Besserer-Offroy, E.*, Berube, P., Cote, J., Murza, A., Longpre, J.M., Dumaine, R., Lesur, O., Auger-Messier, M., Leduc, R., Marsault, E and Sarret, P. (2018). The hypotensive effect of activated apelin receptor is correlated with beta-arrestin recruitment. Pharmacol Res 131 7-16. DOI. (Published).
• Dion, S.P.*, Béliveau, F.*, Désilets, A.*, Ghinet, M.G.*, Leduc, R. (2018). Transcriptome analysis reveals TMPRSS6 isoforms with distinct functionalities. J Cell Mol Med 22 2498-2509. DOI. (Published).
• Li, X., Letourneau, D., Holleran, B.*, Leduc, R., Lavigne, P., Lavoie C. (2017). Galphas protein binds ubiquitin to regulate epidermal growth factor receptor endosomal signaling. Proc Natl Acad Sci USA 114 13477-13482. DOI. (Published).
• Wilkinson, D.J, Habgood, A., Lamb, H.K., Thompson, P., Hawkins, A.R., Désilets, A.*, Leduc, R, Steinmetzer, T., Maya, H., Lee, M.S., Craik, C.S., Watson, S., Hua, L., Milner, J.M., Rowan, A.D. (2017). Matriptase induction of metalloproteinase-dependent aggrecanolysis in vitro and in vivo: promotion of osteoarthritic cartilage damage by multiple mechanisms. Arthritis Rheumatol. 69 (8), 1601-1611. DOI. (Published).
• St-Georges, C.*, Désilets, A.*, Béliveau, F.*, Ghinet, M.*, Dion, S.P*, Colombo, É.*, Boudreault, P.L., Najmanovich, R., Leduc, R and Marsault É. (2017). Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids. Eur J Med Chem 129 110-123. DOI. (Published).
• Perreault, S., de Denus, S., White, M., White-Guay, B., Bouvier, M., Dorais, M., Dubé, M.P., Rouleau, J.L., Tardif, J.C., Jenna, S., Haibe-Kains, B., Leduc, R and Deblois, D. (2017). Older adults with heart failure treated with carvedilol, bisoprolol or metoprolol tartrate: risk of mortality. Pharmacoepidemiol Drug Saf 26 81-90. DOI. (Published).
• Lahey, K.A., Ronaghan, J.J., Shang, J., Dion, S.P.*, Désilets, A.*, Leduc, R, MacNaughton, W.K. (2017). Signaling pathways induced by serine proteases to increase intestinal epithelial barrier function. PLoS One. 12 (7), e0180259. DOI. (Published).
• Murza, A., Sainsily, X., Côté, J., Bruneau-Cossette, L., Besserer-Offroy, E.*, Longpré, J.M., Leduc, R., Dumaine, R., Lesur, O., Auger-Messier, M., Sarret, P., and Marsault, É. (2017). Structure-activity relationship of novel macrocyclic biased apelin receptor agonists. Org Biomol Chem 15 449-458. DOI. (Published).
• Pirisedigh, A., Blais, V., Ait-Mohand, S., Abdallah, K., Holleran, B.J.*, Leduc, R., Dory, Y.L., Gendron, L., Guérin, B. (2017). Synthesis and Evaluation of a 64Cu-conjugate, a selective delta-opioid receptor positron emission tomography imaging agent. Org Lett. 19 2018-2021. DOI. (Published).
• Wilkinson, D.J., Désilets, A.*, Falconer, A., Hsu, Y.C., Lin, H., Hawkins, A., Thompson, P., Ferrell, W.R., Plevin, R., Blain, E., Zhang, Y., Lin, S.W., Leduc, R., Milner, J.M., and Rowan, A.D. (2017). The serine protease hepsin is an activator of pro-matrix metalloproteinase: molecular mechanisms and implications for extracellular matrix turnover. Sci Rep 7 16693. DOI. (Published).
• Besserer-Offroy, E.*, Brouillette, R.L., Lavenus, S.*, Froehlich, U., Brumwell, A.*, Murza, A., Longpré, J.M., Marsault, É., Grandbois, M., Sarret, P., Leduc, R. (2017). The signaling signature of the neurotensin type 1 receptor with endogenous ligands. Eur J Pharmacol. 805 1-13. (Published).
• Lanchec, E.*, Désilets, A.*, Béliveau, F.*, Flamier, A., Mahmoud, S., Bernier, G., Gris, D., Leduc, R.#, Lavoie, C.# # co-corresponding authors. (2017). The type II transmembrane serine protease matriptase cleaves the amyloid precursor protein and reduces its processing to ? amyloid. J Biol Chem 292 20669-20682. DOI. (Published).
• Mona, C.E, Besserer-Offroy, E.*, Cabana, J., Leduc, R., Lavigne, P., Heveker, N., Marsault, É., and Escher, E. (2016). Design, synthesis and biological evaluation of CXCR4 ligands. Organic Biomol Chem 14 10298-10311. (Published).
• Murza, A., Sainsily, X., Coquerel, D., Côté, J., Marx, P., Besserer-Offroy, É.*, Longpré, J.M., Lainé, J., Reversade, B., Salvail, D., Leduc, R., Dumaine, R., Auger-Messier, M., Lesur, O., Sarret, P. and Marsault, É. (2016). Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J Med Chem 59 (7), 2962-2972. DOI. (Published).
• Zoratti, G.L., Tanabe, L.M., Duhaime, M.J., Colombo, É.*, Leduc, R., Marsault, E., Johnson, M.D., Lin, C.Y., Boerner, J., Lang, J.E., List, K. (2016). Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. Oncotarget 7 58162-58173. DOI. (Published).
• Mona C.E., Besserer-Offroy É.*, Cabana J., Lefrançois M., Boulais P.E.*, Lefebvre M.R., Leduc R., Lavigne P., Heveker N., Marsault E., Escher E. (2016). Structure Activity Relationship and Signaling of New Chimeric CXCR4 Agonists. J Med Chem 59 7512-7524. DOI. (Published).
• Monaghan, N.J., Shang, J., Iablokov, V., Zaheer, R., Colarusso, P., Dion, S.*, Désilets, A.*, Leduc, R., Turner, J.R., and MacNaughton, W.K. (2016). The serine protease-mediated increase in intestinal epithelial barrier function is dependent on occludin and requires an intact tight junction. Am J Physiology Gastrointest Liver Physiol 311 G466-G479. DOI. (Published).
• Perreault, S., de Denus, S., White, M., White-Guay, B., Bouvier, M., Dorais, M., Dubé, M.P., Rouleau, J., Tardif, J., Jenna, S., Haibe-Kains, B., Leduc, R., and Deblois, D. (2015). Association of Treatment with carvedilol, bisoprolol and metoprolol on the risk of mortality and hospital admission among older adults with heart failure. Value Health 18 A379. DOI. (Published).
• Murza, A., Besserer-Offroy, E.*, Côté, J., Bérubé, P., Longpré, J.M., Dumaine, R., Lesur, O., Auger-Messier, M., Leduc, R., Sarret, P., and Marsault, E. (2015). C-terminal modifications of apelin-13 significantly change ligand binding, receptor signaling and hypotensive action. J Med Chem 58 2431-2440. (Published).
• Domazet, I., Holleran, B.J.*, Richard, A., Vandengerghe, C., Lavigne, P., Escher, E., Leduc, R. and Guillemette, G. (2015). Characterization of Angiotensin II molecular determinants involved in AT1 receptor functional selectivity. Mol Pharmacol 87 982-995. DOI. (Published).
• Cabana, J., Holleran, B.*, Leduc, R., Escher, E., Guillemette, G., Lavigne, P. (2015). Identification of distinct conformations of the Angiotensin-II Type 1 receptor associated with the Gq/11 protein pathway and the beta-arrestin pathway using molecular dynamics simulations. J Biol Chem 290 15835-15854. DOI. (Published).
• Lecointre, C., Desrues, L., Joubert, J.E., Perzo, N.*, Guichet, P.O., Lejoncour, V., Brulé, C.*, Chabbert, M., Leduc, R., Prézeau, L., Laquerrière, A., Proust, F., Gandolfo, P., Morin, F., and Castel, H. (2015). Signaling switch of the urotensin II receptor: Prototypic chemotaxic mechanism in glioma. Oncogene 34 5080-5094. DOI. (Published).
• Fanelli, R., Besserer-Offroy, É.*, René, A., Côté, J., Tétreault, P., Collerette-Tremblay, J., Longpré, JM., Leduc, R., Martinez, J., Sarret, P., Cavelier, F. (2015). Synthesis and characterization in vitro and in vivo of (l)-(Trimethylsilyl)alanine containing neurotensin analogues. J Med Chem 58 7785-7795. DOI. (Published).
• Zoratti, G., Tanabe, L., Varela, F., Murray, A.S., Berum, C., Colombo, E.*, Lang, J., Molinolo, A., Leduc, R., Marsault, É., Boerner, J., and List, K. (2015). Targeting matriptase in breast cancer abrogates tumor progression via impairment of stromal-epithelial growth factor signalling. Nature Commun 6 6776. DOI. (Published).
• Duchene, D., Colombo, E.*, Désilets, A.*, Boudreault, P.L., Leduc, R., Marsault, É., Najmanovich, R. (2014). Analysis of sub-pocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2. J Med Chem 57 (23), 10198-204. DOI. (Published).
• Brulé, C.*, Perzo, N.*, Joubert, J.E., Sainsily, X., Leduc, R.#, Castel, H.#, Prézeau, L.# (*co-corresponding senior authors). (2014). Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors. FASEB J 28 (12), 5148-5162. DOI. (Published).
• Barré, O., Dufour, A., Béliveau, F.*, Leduc, R., Overall, C.M. (2014). Cleavage specificity analysis of type II transmembrane serine proteases (TTSPs) using PICS on proteome-derived peptide libraries. PLoS One 9 (9), e105984. DOI. (Published).
• Demeule, M., Beaudet, N., Régina, A., Besserer-Offroy, E.*, Murza, A., Tétreault, P., Belleville, K., Ché, C., Larocque, A., Thiot, C., Béliveau, R., Longpré, J.M., Marsault, E., Leduc, R., Lachowicz, J., Gonias, S., Castaigne, J., Sarret, P. (2014). Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J Clin Invest 124 (3), 1199-213. DOI. (Published).
• Sainsily, X., Cabana, J., Holleran, B.J.*, Escher, E., Lavigne, P., Leduc, R. (2014). Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochem Pharmacol 92 (2), 280-8. DOI. (Published).
• Tang, X., Mahajan, S.S., Nguyen, L.T., Béliveau, F.*, Leduc, R., Simon, J.A., Vasioukhin, V. (2014). Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget 5 (5), 1352-62. (Published).
• Boulais, P.E.*, Escher, E., Leduc, R. (2013). Analysis by substituted cysteine scanning mutagenesis of the fourth transmembrane domain of the CXCR4 receptor in its inactive and active state. Biochem Pharmacol 85 (4), 541-50. DOI. (Published).
• Cabana, J., Holleran, B.*, Beaulieu, M.È., Leduc, R., Escher, E., Guillemette, G., Lavigne, P. (2013). Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor. J Biol Chem 288 (4), 2593-604. DOI. (Published).
• Sainsily, X.*, Cabana, J., Boulais, P.E.*, Holleran, B.J.*, Escher, E., Lavigne, P., Leduc, R. (2013). Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochem Pharmacol 86 (11), 1584-93. DOI. (Published).
• Beaulieu, A., Gravel, E., Cloutier, A., Marois, I., Colombo, E.*, Desilets, A.*, Verreault, C., Leduc, R., Marsault, E., Richter, M.V. (2013). Matriptase Proteolytically Activates Influenza Virus and Promotes Multicycle Replication in the Human Airway Epithelium. J Virol 87 (8), 4237-51. DOI. (Published).
• Buzza, M.S., Martin, E.W., Driesbaugh, K.H., Désilets, A.*, Leduc, R., Antalis, T.M. (2013). Prostasin is required for matriptase activation in intestinal epithelial cells to regulate closure of the paracellular pathway. J Biol Chem 288 (15), 10328-37. DOI. (Published).
• Fillion, D., Cabana, J., Guillemette, G., Leduc, R., Lavigne, P., Escher, E. (2013). Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode. J Biol Chem 288 (12), 8187-97. DOI. (Published).
• Colombo, E.*, Désilets, A.*, Duchêne, D., Chagnon, F., Najmanovich, R., Leduc, R., and Marsault, E. (2012). Design and synthesis of potent, selective inhibitors of matriptase. ACS Med Chem Lett 3 (7), 530-534. (Published).
• Murza, A., Parent, A., Besserer-Offroy, E.*, Tremblay, H., Karadereye, F., Beaudet, N., Leduc, R., Sarret, P., Marsault, É. (2012). Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. ChemMedChem 7 (2), 318-25. (Published).
• Netzel-Arnett, S., Buzza, M.S., Shea-Donohue, T., Désilets, A.*, Leduc, R., Fasano, A., Bugge, T.H., Antalis, T.M. (2012). Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm Bowel Dis 18 (7), 1303-14. (Published).
• Lefrançois, M., Lefebvre, M.R., Saint-Onge, G., Boulais, P.E.*, Lamothe, S., Leduc, R., Lavigne, P., Heveker, N., Escher, E. (2011). Agonists for the Chemokine Receptor CXCR4. ACS Med Chem Lett 2 (8), 596-602. (Published).
• Béliveau, F.*, Brulé, C.*, Désilets, A*., Zimmerman, B., Laporte, S.A., Lavoie, C.L., Leduc, R. (2011). Essential role of endocytosis of the type II transmembrane serine protease TMPRSS6 in regulating its functionality. J Biol Chem 286 (33), 29035-43. (Published).
• Bilodeau, J., Désilets, A.*, McDuff, F.O., St-Pierre, C.*, Barbar, E., Leduc, R., Lavigne, P. (2011). Influence of Ca2+ and pH on the folding of the prourotensin II precursor. FEBS Lett 585 (12), 1910-4. (Published).
• Perez-Vargas, J., Shapira, T., Olmstead, A.D., Villanueva, I., Thompson, C.A.H., Ennis, S., Gao, G., DeGuzman, J., Williams, D.E., Wang, M., Chin, A., Bautista-Sanchez, D., Agafitei, O., Levett, P., Xie, X., Nuzzo, G., Freire, V.F., Quintana-Bulla, J.I., Bernardi, D.I., Gubiani, J.R., Suthiphasilp, V., Raksat, A., Meesakul, P., Polbuppha, I., Cheenpracha, S., Jaidee, W., Kanokmedhakul, K., Yenjai, C., Chalyosang, B., Teles, H.P., Manzo, E., Fontana, A., Leduc, R., Boudreault, P.L., Kanokmedhakul, S., Laphoohieo, S., Tietjen, I., Cherkasov, A., Krajden, M., Nabi, I.R., Nikura, M, Shi, P.Y., Andersen, R.J., Jean, F. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antiviral Research (Accepted).

Propriétés intellectuelles

Patents

• Marsault, E., Richter, M., Leduc, R., Colombo, E. Matriptase inhibitors and uses thereof as anti-influenza agents. United States of America. (Granted/Issued).
• Marsault, E., Leduc, R., Richter, M. Methods of using macrocycles as inhibitors of serine protease enzymes. PCT/US2010/053767. United States of America. (Granted/Issued).

Autres contributions

Cours enseignés

• Advanced Biochemical Laboratory. BCM 503. Université de Sherbrooke. Niveau : Undergraduate.
• Autacoïdes and hormones. PHR 702. Université de Sherbrooke. Niveau : Graduate.
• Biomed I. Université de Sherbrooke. Niveau : Undergraduate.
• Principes de Pharmacologie. PHR 701. Université de Sherbrooke. Niveau : Graduate.
• Principles of neurotransmission. PHR 703. Université de Sherbrooke. Niveau : Graduate.
• Seminars in Pharmacology. PHR 610. Université de Sherbrooke. Niveau : Graduate.

Gestion d'évènements

• President. GPCR Retreat. (Conference).

Présentations

• (2022). A molecule to block COVID-19 infection: an interview with Richard Leduc. Radio interview on the scientific radio show Les Années Lumière on Radio-Canada. Canada
• (2022). La COVID a-t-elle encore des as dans sa manche?. Interview for Le Soleil newspaper Quebec city. Canada
• (2022). Un vaporisateur nasal efficace contre les virus respiratoires?. Interview at La Tribune newspaper. Canada
• (2020). Newspaper article on our COVID-19 project. Le Devoir newspaper. Canada
• (2020). Radio interview as part of COVID-19 funding by CIHR. Radio-Canada. Interview. Canada